API
< Back to all clusters
[BUSINESS] · Indonesia · 2 sources

started · updated

BPOM Head Taruna Ikrar promotes pharmaceutical investment and drug independence

Taruna Ikrar, Head of the Indonesian Food and Drug Authority (BPOM), has outlined a new strategic direction for the agency to act as a catalyst for investment in the national pharmaceutical industry. Speaking at the 2026 Indonesia Science, Technology, and Industry Convention (KSTI) in Surabaya, Ikrar emphasized the need to reduce Indonesia's high dependency on imported medicinal raw materials.

To achieve national drug independence, Ikrar proposed a collaboration model involving Academia, Business, and Government (ABG). Under this framework, universities would serve as innovation and research hubs, the business sector would drive investment and industrialization, and the government would provide the necessary regulatory support.

Ikrar also addressed the agency's reputation, noting that BPOM is often perceived by businesses as a hurdle due to lengthy certification and licensing processes. He warned that such delays could discourage investors and impact the national economy. To improve the investment climate, he stated that BPOM must shift its approach from being a mere regulator to a facilitator of industrial growth and health sovereignty.

Entities

BPOM · ITS Surabaya · Indonesia · Taruna Ikrar